AU Patent

AU2024200724B2 — Crystalline forms of N-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Assigned to Agios Pharmaceuticals Inc · Expires 2026-02-05 · 0y expired

What this patent protects

CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL) PIPERAZINE-1-CARBONYL PHENYL)QUINOLINE-8-SULFONAMIDE Provided herein are amorphous and crystalline hemisulfate salt forms of the formula (I). Also provided are pharmaceutical compositions comprising the amorphous and crystalline he…

USPTO Abstract

CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL) PIPERAZINE-1-CARBONYL PHENYL)QUINOLINE-8-SULFONAMIDE Provided herein are amorphous and crystalline hemisulfate salt forms of the formula (I). Also provided are pharmaceutical compositions comprising the amorphous and crystalline hemisulfate salt forms, methods for their manufacture, and uses thereof for treating conditions associated with pymvate kinase such as e.g., pymvate kinase deficiency. CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL) PIPERAZINE-1-CARBONYL PHENYL)QUINOLINE-8-SULFONAMIDE

Drugs covered by this patent

Patent Metadata

Patent number
AU2024200724B2
Jurisdiction
AU
Classification
—
Expires
2026-02-05
Drug substance claim
No
Drug product claim
No
Assignee
Agios Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.